Update: Qinprezo/Dacogen combo stands up
Sunesis reported results from an Phase Ib/II study sponsored by MD Anderson during the European Hematology Association meeting in June 2016, detailing the effect of a combination of Qinprezo and Dacogen for the frontline treatment of patients with acute myeloid leukemia (AML) and those with myelodysplastic syndrome (MDS) unfit for intensive therapy. The 63-person open-label trial demonstrated a median overall survival of 16.1 months at the 70mg/m2 Qinprezo dose, over twice that of either of the drugs alone.Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development of new targeted inhibitors for the treatment of solid and hematologic cancers. The company's primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology and conducting clinical trials. The company's primary program is vecabrutinib, a non-covalent inhibitor of Bruton's Tyrosine Kinase. The company is also developing SNS-510, a phosphoinositide-dependent kinase-1 inhibitor licensed from Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.